Trial Profile
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2024
Price :
$35
*
At a glance
- Drugs Bardoxolone methyl (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Therapeutic Use
- Acronyms LARIAT
- Sponsors Reata Pharmaceuticals
- 11 Oct 2019 According to a Reata Pharmaceuticals media release, safety data from four studies ( NCT03019185, NCT03366337, NCT02316821 and NCT02036970 will be presented at at the American Society of Nephrology Kidney Week 2019 Annual Meeting. Abstract are available on the conference website at https://www.asn-online.org/education/kidneyweek/archives/.
- 08 Jun 2018 Status changed from active, no longer recruiting to completed.
- 31 May 2018 This trial has been completed in Spain (end date: 2018-05-16)